Insulet (NASDAQ: PODD) reported Q1 EPS of ($0.17), $0.02 worse than the analyst estimate of ($0.15). Revenue for the quarter came in at $101.7 million versus the consensus estimate of $97.83 million.

“Every area of our business showed strong momentum and outstanding performance in the first quarter," said Patrick Sullivan, Chairman and Chief Executive Officer. "We continued to execute on our commercial and operational strategies and made great headway on our key initiatives, including our manufacturing and supply chain efforts. This operational progress is driving high product quality, which supports a strong and always improving customer experience. We are investing in innovation to ensure our significant product differentiation and strong business model continue to position Insulet for success in the diabetes and drug delivery markets."

Guidance:

• For the year ending December 31, 2017, the Company is raising the mid-point of its revenue guidance and is now expecting a range of $425 to $440 million (previously $420 to $440 million), compared to 2016 revenue of $367.0 million. This represents year-over-year revenue growth of approximately 18% at the mid-point of the range.
• For the quarter ending June 30, 2017, the Company is introducing revenue guidance in the range of $104 to $108 million, compared to second quarter 2016 revenue of $87.3 million. This represents year-over-year revenue growth of approximately 21% at the mid-point of the range.

For earnings history and earnings-related data on Insulet (PODD) click here.